Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

Inclusion Criteria: * Diagnosis of schizophrenia for a minimum of 1 year before Visit 1 (Screening). * Ability to follow study instructions, complete study assessment tools with minimal assistance and no alteration to the assessment tools, and likely to complete all required visits. * Participant meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for schizophrenia as determined by Structured Clinical Interview for DSM-5 (SCID-5). * Positive and Negative Syndrome Scale (PANSS) total score \>= 70 and \<= 120 at Visit 1 and Visit 2 (Day 1). * Rating of at least 4 (moderate) on at least 2 of the following 4 PANSS positive symptoms; P1: delusions; P2: conceptual disorganization; P3: hallucinatory behaviour; P6: suspiciousness/persecution at Visit 1 and Visit 2. Exclusion Criteria: * Currently meeting DSM-5 criteria for any of the following: * Schizoaffective disorder, schizophreniform disorder, and other psychotic disorders * Bipolar I and II disorder * Autism spectrum disorder, intellectual development disorder, delirium, major/minor neurocognitive disorder * History of meeting DSM-5 criteria for substance-related disorders (excluding caffeine-related and tobacco-related disorders) within the prior 3 months before Visit 1. * Prior participation in any clinical trials involving experimental or investigational drugs within 6 months before Visit 1 or planned during the study. * Female Participants who are pregnant, planning to become pregnant during the course of the study, or are currently lactating.